Systemic TLR7 agonism moderates disease severity in acute DSS-induced colitis in mice

Systemic GS-9620 (vesatolimod) moderates acute DSS-induced colitis severity in mice, with treated animals showing less weight loss, lower Disease Activity Index scores, and protection from colon shortening.

• Why it matters: The contribution of TLR7 to intestinal inflammation is unclear, and there is no approved or clinical-stage IBD therapy that targets this pathway.
• What they did: Mice received systemic GS-9620 during acute DSS-induced colitis, and spleen immunophenotyping assessed Th17/Tr17 and regulatory T cell proportions.
• The result: GS-9620 is associated with reduced Th17 and Tr17 populations and an increased regulatory T cell fraction, suggesting systemic TLR7 agonism shifts immunity toward a regulatory phenotype.

AI summary of the abstract · may contain errors · not medical advice · read the paper.